In the current study, we observed that hepatic expression of the FGF21 coreceptor35, KLB, is reduced in human NAFLD patients, as well as in obese mice, consistent with decreased FGF21 signaling. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.